Table 2.
Laboratory test results
| Data on serum and synovial fluid samples | No. of patients |
|---|---|
| Serum | |
| Serological testing not performed before clinic presentation (n/11) | 5 |
| Seropositive by EIA and IgG immunoblot before presentation to clinic (n/6) | 0 |
| Seropositive by EIA and IgG immunoblot (n/11) | 1 |
| Seropositive by Lyme C6 peptide antibody (n/6) | 1b |
| Synovial fluida | |
| Positive B. burgdorferi DNA PCRs (n/2) | 0 |
| WBC count range (n/12)c | |
| ≤200 cells/mm3 | 2 |
| 201–2,000 cells/mm3 | 4 |
| 2,000–6,000 cells/mm3 | 2 |
| >6,000 cells/mm3 | 4 |
a
Synovial fluid samples were analyzed by commercial laboratories using commercially available immunoblot kits for B. burgdorferi IgM and IgG.
b
The same patient tested positive for EIA, IgG immunoblot, and Lyme C6 peptide antibody.
c
One of the 11 patients had two synovial fluid samples tested from the same joint (separated in time). WBC, white blood cell.